Merck
  • Home
  • Search Results
  • [Efficacy of ACE-inhibitors in patients with recent myocardial infarction. Studies with zofenopril].

[Efficacy of ACE-inhibitors in patients with recent myocardial infarction. Studies with zofenopril].

Giornale italiano di cardiologia (2006) (2012-10-26)
Carlo Lombardi, Anna Isotta Castrini, Marco Metra, Valentina Carubelli, Valentina Lazzarini, Lorenza Inama, Livio Dei Cas
ABSTRACT

Several large-scale trials have demonstrated improved survival with the administration of ACE-inhibitors to patients with a recent myocardial infarction. Many ACE-inhibitors with different pharmacological properties have been shown to be safe and effective. More recently the data provided by the Survival of Myocardial Infarction Long-term Evaluation (SMILE) program indicate that zofenopril may favorably affect the prognosis of patients with a recent myocardial infarction and, according to the results of the SMILE-4 study, it may be superior to ramipril with respect to some variables (cardiovascular hospitalizations) when both these ACE-inhibitors are administered combined with acetylsalicylic acid.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Captopril, meets USP testing specifications
Sigma-Aldrich
Captopril, ≥98% (HPLC), powder
Supelco
Captopril, Pharmaceutical Secondary Standard; Certified Reference Material